Hospitals, drugmakers and national health agencies are turning to blockchain to make medical records, prescriptions and drug shipments tamper-evident rather than merely trusted.
The work spans Estonia's national health records, pharmaceutical tracking by MediLedger and newer trust layers such as Yellow Network.
Key Points
- Estonia runs its national e-health records through a blockchain integrity layer that covers more than 40 million documents.
- U.S. regulators and major drugmakers have piloted blockchain to verify medicines moving through the supply chain.
- Most serious projects keep patient data off the chain, using the ledger only for proofs, audit trails and consent.
Blockchain Records Reach National Scale
Estonia offers the clearest example. Its national health system runs every e-health record through a cryptographic layer that flags any later edit. The country's e-government portal says this guarantees integrity and blocks tampering across more than 40 million documents.
Patients sit at the center of that design. Every resident holds a countrywide digital record, and roughly 2.7 million patient queries pass through the portal each month.
Prescriptions run through the same national identity system, which makes a forged or reused script far easier to catch.
Estonia has also linked more than 200,000 residents' genetic data to their records for precision medicine. The blockchain role stays narrow, covering integrity and access logs rather than the data itself.
MediLedger, a platform built by blockchain firm Chronicled, lets manufacturers and distributors confirm a medicine's identity without one shared database. The U.S. Food and Drug Administration piloted the project with drugmakers and distributors including Pfizer and McKesson. The goal was traceability, not a public record of who bought what.
The effort grew out of the Drug Supply Chain Security Act, the federal law requiring an electronic system to trace prescription drugs. Partners can verify product codes and each other without a single master record.
Hospitals And Insurers Test Ledgers
Everyday medical records show a related weakness. They scatter across providers, give patients little real control, and track who views them poorly, so a breach can sit unnoticed for months.
In Cyprus, VeChain (VET) and partner I-Dante deployed a platform that hands patients direct control of their records. The app complies with EU privacy rules and lets owners decide who can see their data. Mediterranean Hospital of Cyprus became the first to use it.
Patients identify themselves with an encrypted card and manage records through a web app. No data reaches a third party without the owner's approval.
Logistics is another natural fit.
In the United Kingdom, monitoring firm Everyware used Hedera (HBAR) to log freezer temperatures for COVID-19 vaccines at NHS hospitals. The ledger makes those readings hard to alter after the fact. A few degrees off can spoil a dose, so the record's integrity carries real weight.
American insurers and providers chose another route. Avaneer Health, a permissioned network, raised $50 million from backers including Aetna and Cleveland Clinic to speed eligibility checks, prior authorization and claims across rival systems.
The stakes climb sharpest in clinical research.
Regulators inspect only a fraction of trial sites for any given drug. Those visits often surface the same gaps, from protocols ignored to records left incomplete.
A 2026 analysis of 786 trials flagged nearly 30,000 statistical warning signs, with about a third judged real problems rather than noise. Falsified or careless data can push an unsafe drug toward approval. Records that cannot be quietly changed, supporters argue, make that harder to hide.
Software is raising the stakes further. AI tools now help watch trials, reconcile records and flag safety signals, and each is only as good as the data beneath it.
Yellow Network Pitches A Trust Layer
Newer entrants pitch variations on the same theme. Yellow, a trust and settlement layer built on state channels, proposes that each data point be signed the moment it is recorded, then locked so any change breaks the signature. Its team argues the model could fit trials, records and prescriptions alike.
Under that design, signed actions pass between parties off-chain and reach a blockchain only as a final, anchored record. Regulators could in theory watch data as it is captured rather than waiting for an inspection.
Healthcare projects now split by design, from public ledgers that store only hashes to permissioned networks among known partners and private channels that settle later.
The trust layers remain largely untested at scale, with no deployment matching Estonia's reach. Several rivals chase the same problem, and cost and incompatible systems stay stubborn barriers.
Blockchain solves only a narrow problem.
It can prove a record was not altered after entry, but it cannot show whether the first entry was honest. A faked reading, signed at the source, still carries a valid signature.
And cryptography, skeptics note, is rarely the hard part; aligning hospitals, regulators and drugmakers on one system has stalled grander plans before.
Final Thoughts
For all the momentum, the field has learned one lesson the hard way. The grandest version of the idea has quietly faded.
The pattern repeats across records, prescriptions, supply chains and trials alike.
Early hype imagined whole medical histories living on open chains, an approach privacy laws such as HIPAA and GDPR make both risky and impractical. The credible projects now lean on the ledger for proofs, provenance, supply-chain checks and consent, while sensitive records stay encrypted off it. That quieter design, not the original promise, is what hospitals and regulators have agreed to test.
What comes next is less a technological leap than a test of trust between institutions. Whether they settle on one ledger, several, or none, the appetite for records no one can secretly rewrite looks unlikely to fade.